Clinical Oncology Next Generation Sequencing Global Market Report 2025

Description

Next generation sequencing (NGS) is a method employed to determine the sequence of nucleotides within a segment of DNA and is commonly utilized in oncology research. NGS plays a crucial role in identifying rare cancer mutations, detecting carriers of familial cancer mutations, and providing the molecular basis for targeted therapy.

The primary technologies in clinical oncology NGS encompass ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real-time sequencing, ligation sequencing, reversible dye termination sequencing, and nanopore sequencing. Ion semiconductor sequencing is a sequencing technique based on the detection of hydrogen ions released during DNA polymerization. Clinical oncology NGS finds applications in various areas, including screening, companion diagnostics, and other diagnostic purposes, and it is used by a range of end-users, including hospital laboratories, clinical research organizations, and diagnostic laboratories.

The clinical oncology next-generation sequencing market research report is one of a series of new reports from The Business Research Company that provides clinical oncology next-generation sequencing market statistics, including clinical oncology next-generation sequencing industry global market size, regional shares, competitors with a clinical oncology next-generation sequencing market share, detailed clinical oncology next-generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the clinical oncology next-generation sequencing industry. This clinical oncology next-generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clinical oncology next generation sequencing market size has grown rapidly in recent years. It will grow from $0.51 billion in 2024 to $0.58 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to genomic research advances, cancer biomarker discovery, technological advancements, regulatory approvals.

The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to growing cancer incidence, precision medicine, immuno-oncology, liquid biopsies. Major trends in the forecast period include comprehensive genomic profiling (cgp), immuno-oncology, tumor evolution and heterogeneity, ai and machine learning.

The increasing number of cancer cases worldwide is expected to be a contributing factor to the growth of the clinical oncology next-generation sequencing market in the foreseeable future. In 2021, the USA alone reported 1.9 million new cancer cases and 0.6 million cancer-related deaths, according to data from the American Cancer Society. The most common cancer types globally include lung, prostate, colorectal, and breast cancer, accounting for 43% of all new cancer cases. Consequently, the rising global incidence of cancer is likely to drive demand and foster growth in the clinical oncology next-generation sequencing market.

The rising prevalence of cancer is expected to drive the growth of the clinical oncology next-generation sequencing (NGS) market. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. NGS plays a vital role in detecting novel and rare mutations in cancer, helping to better understand the molecular foundations of individual tumors. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that there were approximately 18.1 million cancer survivors in the United States. This number is projected to increase to 22.5 million by 2032. By 2040, the number of new cancer cases annually is expected to reach 29.9 million, with cancer-related deaths estimated to rise to 15.3 million. Therefore, the growing prevalence of cancer is a major factor driving the expansion of the clinical oncology next-generation sequencing market.

Companies in the clinical oncology next-generation sequencing market are increasingly investing in workflow automation to enhance precision and reduce sample-to-sample variability. For example, Agilent automation solutions have developed an automated system that enables a higher number of parallel reactions, reduces sample processing time, increases the volume of processed samples, and minimizes variability between samples. Additionally, companies like Sophia Genetics are focusing on data-driven medicine and the automation of DNA sequencing to enhance diagnostic and treatment capabilities.

Major companies operating in the clinical oncology next-generation sequencing market are introducing innovative products like the BenchMark ULTRA PLUS system to enhance their market competitiveness. The BenchMark ULTRA PLUS System is a valuable tool for clinical laboratories, particularly those involved in cancer diagnostics and research, as it ensures the accuracy and efficiency of diagnostic tests, ultimately contributing to improved patient care. For example, in June 2022, the Switzerland-based pharmaceutical company Roche unveiled the BenchMark ULTRA PLUS system, their state-of-the-art platform for tissue staining. This system provides clinicians with rapid and accurate test results, aiding in timely treatment decisions for patients.

In January 2023, Agilent Technologies, a US-based scientific equipment manufacturer, acquired Avida Biomed for an undisclosed amount. This acquisition aims to strengthen Agilent Technologies' high-performance target enrichment workflows for next-generation sequencing applications, particularly in cancer research. By integrating Avida's innovative technologies, Agilent seeks to enhance precision medicine approaches and expand its SureSelect portfolio into the clinical research and diagnostics markets. Avida Biomed, a US-based biotechnology company, specializes in clinical oncology next-generation sequencing.

Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

North America was the largest region in the clinical oncology next-generation sequencing market in 2024. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the clinical oncology next generation sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The clinical oncology next-generation sequencing market consists of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductors sequencing, pyro-sequencing, synthesis sequencing (SBS), real-time sequencing (SMRT), ligation sequencing, and other techniques that are used in oncology research for determining the nucleotide sequence leading to clinical oncology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Clinical Oncology Next Generation Sequencing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on clinical oncology next generation sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for clinical oncology next generation sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The clinical oncology next generation sequencing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Technology: Ion Semiconductor Sequencing; Pyro-Sequencing; Synthesis Sequencing; Real Time Sequencing; Ligation Sequencing; Reversible Dye Termination Sequencing; Nano-Pore Sequencing
2) By Application: Screening; Companion Diagnostics; Other Diagnostics
3) By End User: Hospital Laboratories; Clinical Research Organizations; Diagnostic Laboratories
Subsegments:
1) By Ion Semiconductor Sequencing: Ion Proton System; Ion PGM System; Ion S5 System; Other Ion Semiconductor Sequencing Technologies
2) By Pyro-Sequencing: 454 Pyrosequencing; Other Pyro-Sequencing Technologies
3) By Synthesis Sequencing: Illumina Sequencing Technology; SOLiD Sequencing Technology; Other Synthesis Sequencing Technologies
4) By Real-Time Sequencing: PacBio RS II System; Sequel System; Other Real-Time Sequencing Technologies
5) By Ligation Sequencing: Helicos Single Molecule Sequencing; Other Ligation Sequencing Technologies
6) By Reversible Dye Termination Sequencing: Illumina HiSeq; Illumina NextSeq; Other Reversible Dye Termination Sequencing Technologies
7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION); Other Nano-Pore Sequencing Technologies
Companies Mentioned: Thermo Fisher Scientific; Oxford Nanopore Technologies Ltd.; QIAGEN N.V.; Myriad Genetics Inc.; Illumina Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r32453

1. Executive Summary

2. Clinical Oncology Next Generation Sequencing Market Characteristics

3. Clinical Oncology Next Generation Sequencing Market Trends And Strategies

4. Clinical Oncology Next Generation Sequencing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Clinical Oncology Next Generation Sequencing Growth Analysis And Strategic Analysis Framework

5.1. Global Clinical Oncology Next Generation Sequencing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Clinical Oncology Next Generation Sequencing Market Growth Rate Analysis
5.4. Global Clinical Oncology Next Generation Sequencing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Clinical Oncology Next Generation Sequencing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Clinical Oncology Next Generation Sequencing Total Addressable Market (TAM)

6. Clinical Oncology Next Generation Sequencing Market Segmentation

6.1. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ion Semiconductor Sequencing
Pyro-Sequencing
Synthesis Sequencing
Real Time Sequencing
Ligation Sequencing
Reversible Dye Termination Sequencing
Nano-Pore Sequencing
6.2. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Screening
Companion Diagnostics
Other Diagnostics
6.3. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Laboratories
Clinical Research Organizations
Diagnostic Laboratories
6.4. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Ion Semiconductor Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ion Proton System
Ion PGM System
Ion S5 System
Other Ion Semiconductor Sequencing Technologies
6.5. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Pyro-Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
454 Pyrosequencing
Other Pyro-Sequencing Technologies
6.6. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Synthesis Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Illumina Sequencing Technology
SOLiD Sequencing Technology
Other Synthesis Sequencing Technologies
6.7. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Real-Time Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
PacBio RS II System
Sequel System
Other Real-Time Sequencing Technologies
6.8. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Ligation Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Helicos Single Molecule Sequencing
Other Ligation Sequencing Technologies
6.9. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Reversible Dye Termination Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Illumina HiSeq
Illumina NextSeq
Other Reversible Dye Termination Sequencing Technologies
6.10. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Nano-Pore Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oxford Nanopore Technologies (MinION, GridION, PromethION)
Other Nano-Pore Sequencing Technologies

7. Clinical Oncology Next Generation Sequencing Market Regional And Country Analysis

7.1. Global Clinical Oncology Next Generation Sequencing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Clinical Oncology Next Generation Sequencing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Clinical Oncology Next Generation Sequencing Market

8.1. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Clinical Oncology Next Generation Sequencing Market

9.1. China Clinical Oncology Next Generation Sequencing Market Overview
9.2. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Clinical Oncology Next Generation Sequencing Market

10.1. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Clinical Oncology Next Generation Sequencing Market

11.1. Japan Clinical Oncology Next Generation Sequencing Market Overview
11.2. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Clinical Oncology Next Generation Sequencing Market

12.1. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Clinical Oncology Next Generation Sequencing Market

13.1. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Clinical Oncology Next Generation Sequencing Market

14.1. South Korea Clinical Oncology Next Generation Sequencing Market Overview
14.2. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Clinical Oncology Next Generation Sequencing Market

15.1. Western Europe Clinical Oncology Next Generation Sequencing Market Overview
15.2. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Clinical Oncology Next Generation Sequencing Market

16.1. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Clinical Oncology Next Generation Sequencing Market

17.1. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Clinical Oncology Next Generation Sequencing Market

18.1. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Clinical Oncology Next Generation Sequencing Market

19.1. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Clinical Oncology Next Generation Sequencing Market

20.1. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Clinical Oncology Next Generation Sequencing Market

21.1. Eastern Europe Clinical Oncology Next Generation Sequencing Market Overview
21.2. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Clinical Oncology Next Generation Sequencing Market

22.1. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Clinical Oncology Next Generation Sequencing Market

23.1. North America Clinical Oncology Next Generation Sequencing Market Overview
23.2. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Clinical Oncology Next Generation Sequencing Market

24.1. USA Clinical Oncology Next Generation Sequencing Market Overview
24.2. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Clinical Oncology Next Generation Sequencing Market

25.1. Canada Clinical Oncology Next Generation Sequencing Market Overview
25.2. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Clinical Oncology Next Generation Sequencing Market

26.1. South America Clinical Oncology Next Generation Sequencing Market Overview
26.2. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Clinical Oncology Next Generation Sequencing Market

27.1. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Clinical Oncology Next Generation Sequencing Market

28.1. Middle East Clinical Oncology Next Generation Sequencing Market Overview
28.2. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Clinical Oncology Next Generation Sequencing Market

29.1. Africa Clinical Oncology Next Generation Sequencing Market Overview
29.2. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Clinical Oncology Next Generation Sequencing Market Competitive Landscape And Company Profiles

30.1. Clinical Oncology Next Generation Sequencing Market Competitive Landscape
30.2. Clinical Oncology Next Generation Sequencing Market Company Profiles
- 30.2.1. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Oxford Nanopore Technologies Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. QIAGEN N.V. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Clinical Oncology Next Generation Sequencing Market Other Major And Innovative Companies

31.1. F. Hoffmann-La Roche Ltd.
31.2. PerkinElmer Inc.
31.3. Agilent Technologies Inc.
31.4. Pacific Biosciences of California Inc.
31.5. Caris Life Sciences
31.6. Paradigm Diagnostics
31.7. GATC Biotech AG
31.8. Macrogen Inc.
31.9. DNASTAR Inc.
31.10. Exosome Diagnostics Inc.
31.11. Biomatters Ltd.
31.12. Partek Inc.
31.13. Foundation Medicine Inc.
31.14. Becton Dickinson and Company (BD)
31.15. Takara Bio Inc.

32. Global Clinical Oncology Next Generation Sequencing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Clinical Oncology Next Generation Sequencing Market

34. Recent Developments In The Clinical Oncology Next Generation Sequencing Market

35. Clinical Oncology Next Generation Sequencing Market High Potential Countries, Segments and Strategies

35.1 Clinical Oncology Next Generation Sequencing Market In 2029 - Countries Offering Most New Opportunities
35.2 Clinical Oncology Next Generation Sequencing Market In 2029 - Segments Offering Most New Opportunities
35.3 Clinical Oncology Next Generation Sequencing Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer